Hafnia alvei HA4597 Strain Reduces Food Intake and Body Weight Gain and Improves Body Composition, Glucose, and Lipid Metabolism in a Mouse Model of Hyperphagic Obesity.

Marie-Anne Le Solliec,Grégory Lambert,Camille Deroissart,Fatima Léon,Sergueï O Fetissov,Romain Legrand,Saïda Azhar,Nicolas Lucas,Manon Dominique,Jean-Claude Do Rego,Pierre Déchelotte

doi:10.3390/microorganisms8010035

Abstract

Use of new generation probiotics may become an integral part of the prevention and treatment strategies of obesity. The aim of the present study was to test the efficacy of a potential probiotic strain of lactic bacteria Hafnia alvei (H. alvei) HA4597™, in a mouse model of obesity characterized by both hyperphagia and diet-induced adiposity. For this purpose, 10-week-old high-fat-diet (HFD)-fed hyperphagic ob/ob male mice received a daily treatment with 1.4 × 1010 CFU of H. alvei for 38 days. Effects of H. alvei were compared to those of a lipase inhibitor orlistat (80 mg/kg daily) and a vehicle (NaCl 0.9%) in HFD-fed ob/ob mice. A control untreated group of ob/ob mice received the standard diet throughout the experiment. The vehicle-treated HFD group displayed increased food intake, worsening of adiposity, and glycemia. Treatment with H. alvei was accompanied by decreased body weight and fat-mass gain along with reduced food intake to the level of the standard-diet-fed mice. At the end of the experiment, the group treated with H. alvei showed a decrease of glycemia, plasma total cholesterol, and alanine aminotransferase. The orlistat-treated mice showed a lower rate of body weight gain but were hyperphagic and hyperglycemic. These results demonstrate the beneficial anti-obesity and metabolic effects of H. alvei HA4597™ in mice with obesity resulting from hyperphagia and diet-induced adiposity.

Highlights

According to the World Health Organization, the global prevalence of overweight (BMI ≥ 25 kg/m2) and obesity (BMI ≥ 30 kg/m2) has tripled since 1975, affecting about 39% and 13%, respectively, of adults in 2016 and about 381 million children and adolescents [1]
Existence of the functional link between gut microbiota and host regulation of appetite and energy metabolism indicates that some gut commensal bacteria can be potentially identified and developed as new-generation anti-obesity probiotics based on the understanding of their mechanisms of action [10]
We have recently demonstrated that a Hafnia alvei (H. alvei) HA4597TM strain of commensal bacteria of the Hafniaceae family belonging to the order of Enterobacteriales displays anti-obesity properties in two animal models of obesity, standard-diet-fed leptin-deficient ob/ob and high-fat-diet (HFD)-fed wild-type (WT) mice [11]

Summary

Introduction

According to the World Health Organization, the global prevalence of overweight (BMI ≥ 25 kg/m2) and obesity (BMI ≥ 30 kg/m2) has tripled since 1975, affecting about 39% and 13%, respectively, of adults in 2016 and about 381 million children and adolescents [1]. Gut microorganisms have recently been implicated in the regulation of host energy metabolism by showing the associations of gut microbiota composition with healthy or obese phenotypes [4,5]. The molecular pathways linking gut microbiota to the brain regulation of energy balance are not yet fully understood, modulation of gut microbiota composition by supplementing beneficial to health bacteria appears as an appealing new strategy for obesity prevention and treatment. Existence of the functional link between gut microbiota and host regulation of appetite and energy metabolism indicates that some gut commensal bacteria can be potentially identified and developed as new-generation anti-obesity probiotics based on the understanding of their mechanisms of action [10]

Objectives

Results

Discussion

Conclusion